Zacks Investment ResearchThu, 30 Apr 2026 13:35:16 GMTPhathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue EstimatesAXSM+1.82%
Investors Business DailyThu, 16 Apr 2026 18:31:24 GMTBiotech Stock Knocks At $2 Billion Opportunity, Nears Buy PointAXSM+1.82%
Zacks Investment ResearchWed, 25 Mar 2026 16:31:42 GMTWhy Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?AXSM+1.82%
The Motley FoolWed, 18 Mar 2026 15:37:30 GMTThis New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock GainAXSM+1.82%
Seeking AlphaTue, 10 Mar 2026 23:40:17 GMTAxsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 TranscriptAXSM+1.82%
The Motley FoolMon, 09 Mar 2026 19:43:48 GMTAxsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA DecisionAXSM+1.82%
Zacks Investment ResearchTue, 24 Feb 2026 18:11:07 GMTAXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity SalesAXSM+1.82%
Seeking AlphaMon, 23 Feb 2026 17:25:35 GMTAxsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be OvervaluedAXSM+1.82%
Zacks Investment ResearchMon, 23 Feb 2026 17:00:51 GMTHere's What Key Metrics Tell Us About Axsome (AXSM) Q4 EarningsAXSM+1.82%
Zacks Investment ResearchMon, 23 Feb 2026 16:35:40 GMTAxsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue EstimatesAXSM+1.82%
Seeking AlphaMon, 23 Feb 2026 16:34:58 GMTAxsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call TranscriptAXSM+1.82%
The Motley FoolSun, 22 Feb 2026 06:00:00 GMTGot $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036AXSM+1.82%
Zacks Investment ResearchMon, 16 Feb 2026 16:00:31 GMTAxsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy?AXSM+1.82%
The Motley FoolThu, 05 Feb 2026 14:00:00 GMTShould You Buy Axsome Therapeutics Stock Before Feb. 23?AXSM+1.82%
